Frontlight ResearchEarly access
Active, not recruitingNo phase
EDX110 Randomized Control Trial for Treatment of DFUs
Key facts
- Who runs it
- ConvaTec Inc.
- Where
- Flagami, Los Angeles, McAllen, O'Fallon, Phoenix, Portland, San Antonio, Santa Ana, and Vista, United StatesSee the 9 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 300 people enrolled
- Started
- 30 Oct 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EDX110
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study
- The participant must have an index ulcer meeting the following characteristics:; Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory; Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue; Located on the anatomical foot; defined as distal to the medial or lateral malleolus
- Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema >0.5 but <2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge
- Ulcer duration at randomization must be present for ≥1 month but less than <24 months in duration
- Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2
- If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:; The ulcer with the largest wound area, as long as it meets all other criteria; ≥3cm distance from any other ulcer on the affected limb
- Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history)
- HgbA1c <12% (NGSP) OR 108 mmol/mol (IFCC) OR average blood glucose 298 mg/DL
- Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD)
- Participants are required to have either; Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5; OR Dorsum transcutaneous oxygen test (TcPO2): >40 mm/Hg
Who cannot take part
- Participants receiving any of the following prior therapies. In the last 30 days:; Has required systemic corticosteroids >10mg/kg/day OR; Participant has required Chemoradiation (chemotherapy and/or radiation therapy) to treat cancer and is immunocompromised OR; Participant is anticipated to require such medications during the study period; Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix); Has undergone any amputation to the affected leg
- Concurrent enrolment in any other study
- Participants with wounds that have any of the following characteristics:; Wagner Grade 2 - ulcers extend into tendon, bone, or capsule; Grade 3 - deep ulcer with osteomyelitis, or abscess; Grade 4 - partial foot gangrene; Grade 5 - whole foot gangrene
- Infections that are classified as:; PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone); PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome [SIRS]); In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture/histopathology of a bone specimen; OR Cellulitis/lymphangitis/soft tissue gas or necrotizing fasciitis originating from the wound site
- Known or suspected local skin malignancy at the site of the ulcer
- A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis)
- Known hypersensitivity to constituents of the product
- Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator
- Wound duration >2 years
- Women of childbearing age (women aged <55 years who have not undergone menopause) who are:; Pregnant at time of enrolment; Breast-feeding
- Tunnelling, Cavity or undermining wounds
- Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities
- Active Charcot deformity
Where in United States
Also in 1 other country, 1 site
- Herco Medical CenterFlagami, United States
- Keck Medicine of USCLos Angeles, United States
- Futuro Clinical TrialsMcAllen, United States
- Gateway Clinical TrialsO'Fallon, United States
- Advanced Foot CarePhoenix, United States
- OHSUPortland, United States
- University of Texas Health Science CenterSan Antonio, United States
- Clemente Clinical ResearchSanta Ana, United States
- ILD Research CenterVista, United States
About the trial
What the trial wants to find out
Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.
The 2 groups in the trial
- EDX110 with Standard of Care (SOC)Existing treatment, for comparison
Diabetic Foot Ulcer (DFU) DFU treatment with EDX110 wound dressing and SOC
Treatment: EDX110
- Standard of Care (SOC)No study treatment, for comparison
Diabetic Foot Ulcer (DFU) DFU treatment with using only traditional Standard of Care (SOC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Centre, Observer-Blinded, Randomized Controlled Trial of EDX110 for the Treatment of Diabetic Foot Ulcers
- Record updated
- 2 November 2026